TY - BOOK AU - Ahmed Mohammad Mohi Eldin Ali AU - Foaad Mohammad Abutaleb , AU - Hussain Mostafa Khaled , AU - Nadia Mahmoud Mokhtar , TI - Treatment tailored therapy of diffuse large B-cell non hodgkin's lymphoma / PY - 2012/// CY - Cairo : PB - Ahmed Mohammad Mohi Eldin Ali , KW - CD20-positive diffuse large B-cell lymphoma KW - R-CHOP KW - Rituximab N1 - Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology-Medical; Issued also as CD N2 - CD20-positive diffuse large B-cell lymphoma (DLBCL) accounts for approximately 40% of new cases of lymphoma. DLBCL is a heterogeneous disease that includes at least two prognostically important subtypes (i.e. germinal center B-cell like [GCB] and non-germinal center B-cell like [non-GCB]). These subtypes initially were characterized by gene expression profiling and subsequently were confirmed by immunostaining UR - http://172.23.153.220/th.pdf ER -